Adherex Technologies Inc.

Adherex Technologies Inc.

July 28, 2005 08:00 ET

Adherex to Present at America's Growth Capital Second Annual Growth Conference on August 1, 2005

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - July 28, 2005) - Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it will participate in the America's Growth Capital 2nd Annual Growth Conference on Monday, August 1, 2005 at 1:30 p.m. ET. Adherex's presentation will be webcast live and can be accessed through the investor relations section of the Company's website at The conference is being held at the Boston Marriott, Copley Place, Boston, MA.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in development including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, a dihydropyrimidine dehydrogenase (DPD) inhibitor, is being developed to enhance the therapeutic value and effectiveness of 5-FU, one of the most widely-used oncology drugs in the world. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484